AXS Investments’s Biogen BIIB Stock Holding History

AXS Investments’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-6,185	Closed	-$1.2M	–	220
2024 Q3	$1.2M	Buy	+6,185	New	+$1.29M	0.32%	168

Other funds holding BIIB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Pacer Advisors Malvern, Pennsylvania $39.3B AUM 27.96% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

AXS Investments's BIIB Position: Q4 2024 in Review

AXS Investments sold out of Biogen (BIIB) in Q4 2024, closing a stake of 6,185 shares — an estimated $1.2M sold.

AXS Investments first reported a position in BIIB in Q3 2024 and held it in 1 quarter. The position peaked at $1.2M in Q3 2024. 876 funds tracked by Wall St. Rank hold BIIB as of Q4 2024.

AXS Investments reported no remaining Biogen position as of Q4 2024 after selling out during the quarter.
AXS Investments sold 6,185 Biogen shares in Q4 2024, an estimated $1.2M.
AXS Investments first reported a position in Biogen in Q3 2024 and held it in 1 quarter.
AXS Investments's Biogen position peaked at $1.2M in Q3 2024.
876 funds tracked by Wall St. Rank held Biogen as of Q4 2024.

Based on AXS Investments's 13F filing for Q4 2024, filed 10 Feb 2025.